You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. An adjuvanted influenza vaccine platform for dose sparing, multiplexing, and rapid deployment

    SBC: POP Biotechnologies Inc.            Topic: NIAID

    Abstract Influenza is the cause of considerable morbidity and mortality globally. Certain groups, i.e., infants, pregnant young women, and older adults are especially at risk for severe disease. Despite immunization being the most effective and economical prophylactic approach, vaccines often provide less than optimal defense against an influenza illness, with efficacies ranging from 10-60%. This ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. A PET Diagnostic for Imaging Bacterial Infection

    SBC: CHRONUS PHARMACEUTICALS, INC.            Topic: NIBIB

    PROJECT SUMMARY Bacterial infections such as those of prosthetic joints, bones (osteomyelitis) and heart valves (infective endocarditis) are difficult to diagnose and treat, and are a major cause of mortality, morbidity and health care costs. The long-term goal of our program is to develop a positron emission tomography (PET) radiotracer that can be used for non-invasive PET imaging to detect and ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. CNS Gene Therapy for CLN2 Disease Using Parallel Multiple Routes of Administration

    SBC: LEXEO Therapeutics LLC            Topic: NINDS

    Abstract. In partnership with the Crystal laboratory, Weill Cornell, LEXEO is developing an adeno-associ- ated virus (AAV)-based gene therapy to treat the central nervous system (CNS) manifestations of CLN2 (Batten) disease, a fatal, childhood autosomal recessive neurodegenerative lysosomal storage disorder caused by mutations in the CLN2 gene, coding for a lysosomal enzyme, tripeptidyl peptidase ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. Preventing outbreaks of foodborne pathogenic bacteria in edible sprouts via novel resistance-conferring seed treatments

    SBC: Ascribe Bioscience Inc.            Topic: NIAID

    Abstract One of the most severe foodborne outbreaks in Europe, and the second-largest “Shiga toxin-producing” E. coli outbreak worldwide, was traced to E. coli O104: H4 in fresh fenugreek sprouts from a farm in Germany. It affected more than 4,075 individuals in 16 countries and included 908 cases complicated by hemolytic uremic syndrome (HUS) and 50 deaths. In the U.S., sprouts were implicate ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. Gene Therapy to Treat Ethanol-induced Osteoporosis Associated with Aldehyde Dehydrogenase 2 Deficiency

    SBC: LEXEO Therapeutics LLC            Topic: 999

    Abstract. LEXEO Therapeutics, LLC, is an early stage biotechnology company focused on using in vivo gene therapy technologies to treat hereditary disorders of unmet medical need. LEXEO is developing an in vivo gene therapy strategy to mitigate the high risk for osteoporosis in individuals with aldehyde dehydro- genase 2 (ALDH2) deficiency, a hereditary disorder affecting 8% of the world population ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. Interstitial Chemophototherapy with Light-Activated Nanoparticulate Doxorubicin

    SBC: POP Biotechnologies Inc.            Topic: 102

    SUMMARY Our goal is to advance the commercialization of interstitial chemo-phototherapy (I-CPT) as a potent antitumor therapeutic option for locally advanced tumors. This application will focus on providing a proof of concept for the benefit of I-CPT in the treatment locally advanced hepatocellular carcinoma (HCC). Patients with inoperable locally advanced HCC have a poor prognosis with a 5-year s ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Modulation of the gut microbiome to enhance efficacy of immunotherapy in pancreatic adenocarcinoma

    SBC: Periomics Care LLC            Topic: 102

    Abstract Pancreatic ductal adenocarcinoma (PDA) is among the ten most common cancers for both men and women. According to CDC the incidence rates of pancreatic cancer have been rising by almost 1.2% each year over the last 10 years. The 5-year survival rate is less than 7%. Despite the recent success of checkpoint blockade- based monotherapy in human melanoma and non-small cell lung cancer, many P ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Antioxidant enzyme-loaded Pro-NP for treatment of TBI.

    SBC: ProTransit Nanotherapy, LLC            Topic: 106

    ABSTRACT Traumatic brain injury (TBI) is one of the leading causes of death and disability worldwide and comes with a significant economic burden associated with emergency room visits and hospitalizations. Oxidative stress- mediated secondary injury post-TBI is a considerable risk factor for mortality and long-term impairment. Immediately following TBI, a cascade of biological responses leads to i ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. An Economical Point-of-Care Software Solution Prototype for Medication Prior Authorization

    SBC: Breezmed            Topic: 104

    ABSTRACT This STTR Phase I project uses mixed-method formative evaluation strategies to develop, test, and evaluate an alpha prototype of Breezmed, a point-of-care electronic prior authorization web-based platform. Prior authorization burdens the current medical system, hampering a provider’s ability to efficiently prescribe medication and in a timely fashion. This often leads to treatment non-c ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Refinement of a rapid saliva miRNA diagnostic test for concussion

    SBC: Quadrant Biosciences Inc.            Topic: NINDS

    Summary/Abstract - Quadrant Biosciences is developing a new diagnostic to aid in the clinical detection of mild traumatic brain injury (mTBI) in school-aged children and young adults (13–22 years). Based on salivary microRNA (miRNA) biomarkers, Quadrant’s diagnostic will provide an accurate, objective, and non-invasive method for mTBI diagnosis. Such a method is critically needed, as the numbe ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government